1.14
-0.0104(-0.91%)
Currency In NOK
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
13
First IPO Date
December 13, 2017
| Name | Title | Pay | Year Born |
| Mr. Olav Hellebo BBA, MBA | Chief Executive Officer | 0 | 1965 |
| Mr. Rune Skeie | Chief Financial Officer | 2.68M | 1973 |
| Ms. Cristina Oliva M.D. | Chief Medical Officer | 5.28M | N/A |
| Ms. Gayle M. Mills M.B.A | Chief Business Officer | 0 | 1955 |
| Graham Morell | Head of IR | 0 | N/A |
| Dr. Akil Jackson | Medical Director | 0 | N/A |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
